Evaluation of the PK Profile of Firibastat Following Administration of Firibastat Prototype Tablet Formulations
Status:
Completed
Trial end date:
2019-06-07
Target enrollment:
Participant gender:
Summary
This is a single-centre, open-label, non-randomised, period fixed sequence study designed to
investigate the PK and safety of Firibastat (QGC001) modified release (MR) prototype tablet
formulations and compare this to a reference Firibastat (QGC001) immediate release (IR)
capsule formulation in healthy male subjects.
It is planned to enrol 12 subjects to receive single oral doses of investigational medicinal
product (IMP).